ERBB2 and gastric cancer: Zhang et al. used CTCs to track trastuzumab resistance in HER2-positive GC (63); Overall, liquid biopsy supports early detection, treatment adjustment, and non-invasive monitoring in GC, with Jung SH et al. reinforcing its value in HER2-targeted therapy (48).